These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16870100)

  • 1. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab.
    Gonzalez-Juanatey C; Llorca J; Sanchez-Andrade A; Garcia-Porrua C; Martin J; Gonzalez-Gay MA
    Clin Exp Rheumatol; 2006; 24(3):309-12. PubMed ID: 16870100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients.
    Sidiropoulos PI; Siakka P; Pagonidis K; Raptopoulou A; Kritikos H; Tsetis D; Boumpas DT
    Scand J Rheumatol; 2009; 38(1):6-10. PubMed ID: 18991190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody.
    Gonzalez-Juanatey C; Testa A; Garcia-Castelo A; Garcia-Porrua C; Llorca J; Gonzalez-Gay MA
    Arthritis Rheum; 2004 Jun; 51(3):447-50. PubMed ID: 15188332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis.
    Kerekes G; Soltész P; Szucs G; Szamosi S; Dér H; Szabó Z; Csáthy L; Váncsa A; Szodoray P; Szegedi G; Szekanecz Z
    Isr Med Assoc J; 2011 Mar; 13(3):147-52. PubMed ID: 21608334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(4):373-9. PubMed ID: 16956426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.
    Hürlimann D; Forster A; Noll G; Enseleit F; Chenevard R; Distler O; Béchir M; Spieker LE; Neidhart M; Michel BA; Gay RE; Lüscher TF; Gay S; Ruschitzka F
    Circulation; 2002 Oct; 106(17):2184-7. PubMed ID: 12390945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation.
    Capria A; De Nardo D; Baffetti FR; Barbini U; Violo A; Tondo T; Fontana L
    Int J Immunopathol Pharmacol; 2010; 23(1):255-62. PubMed ID: 20378011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis.
    Bosello S; Santoliquido A; Zoli A; Di Campli C; Flore R; Tondi P; Ferraccioli G
    Clin Rheumatol; 2008 Jul; 27(7):833-9. PubMed ID: 18075712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.
    Gonzalez-Gay MA; De Matias JM; Gonzalez-Juanatey C; Garcia-Porrua C; Sanchez-Andrade A; Martin J; Llorca J
    Clin Exp Rheumatol; 2006; 24(1):83-6. PubMed ID: 16539824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Treatments for Rheumatoid Arthritis on Endothelial Dysfunction Evaluated by Flow-Mediated Vasodilation in Patients with Rheumatoid Arthritis.
    Kotani K; Miyamoto M; Ando H
    Curr Vasc Pharmacol; 2017; 15(1):10-18. PubMed ID: 27739363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy.
    Gonzalez-Juanatey C; Vazquez-Rodriguez TR; Miranda-Filloy JA; Gomez-Acebo I; Testa A; Garcia-Porrua C; Sanchez-Andrade A; Llorca J; González-Gay MA
    Mediators Inflamm; 2012; 2012():674265. PubMed ID: 22899879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis.
    Capsoni F; Sarzi-Puttini P; Atzeni F; Minonzio F; Bonara P; Doria A; Carrabba M
    Arthritis Res Ther; 2005; 7(2):R250-5. PubMed ID: 15743471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study.
    Sandoo A; Kitas GD; Carroll D; Veldhuijzen van Zanten JJ
    Arthritis Res Ther; 2012 May; 14(3):R117. PubMed ID: 22594788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.